← Back to Search

Behavioural Intervention

AIH first for Multiple Sclerosis

N/A

Waitlist Available

Research Sponsored by Shirley Ryan AbilityLab

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Relapse free for at least 6 months

Expanded Disability Status Scale (EDSS) ≤7

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately before the intervention and immediately after the intervention.

Awards & highlights

Study Summary

"This trial aims to see how breathing low levels of oxygen in short bursts, known as Acute Intermittent Hypoxia (AIH), can improve arm function in people with multiple sclerosis (

Who is the study for?

This trial is for individuals with Multiple Sclerosis (MS) who are interested in a breathing intervention that may improve arm and hand function. Specific eligibility criteria details were not provided, so participants should inquire further to determine if they qualify.Check my eligibility

What is being tested?

The study tests the effects of Acute Intermittent Hypoxia (AIH), which involves breathing low oxygen levels briefly, on neural pathways and arm function in MS patients. It compares AIH with a sham procedure to assess changes in muscle response and brain signals.See study design

What are the potential side effects?

While specific side effects are not listed, AIH generally involves risks associated with low oxygen levels such as lightheadedness or shortness of breath. Participants should discuss potential side effects with the research team.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been free from cancer relapse for at least 6 months.

Select...

I can walk with assistance.

Select...

My index finger is weak or I am slow at the peg test with one hand.

Select...

My current medication for my condition has been stable for at least 6 months.

Select...

I have been on the same daily dose of dalfampridine for at least 2 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediately before the intervention and immediately after the intervention.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediately before the intervention and immediately after the intervention.

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately before the intervention and immediately after the intervention. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Accuracy of Direction Estimation of Passive Joint Movement

Changes in Spinal Reflex Threshold

Motor Evoked Potentials (MEPs) in First Dorsal Interosseous (FDI)

+1 more

Secondary outcome measures

Box and Block Test

Grip Strength

Index Finger Abduction Force

+6 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Sham FirstExperimental Treatment2 Interventions

Participants in the this arm will undergo 2 sessions of Sham AIH each separated by a 1-week washout period. 1 week later, participants will undergo 2 sessions of AIH also separated by a 1-week washout period.

Group II: AIH firstExperimental Treatment2 Interventions

Participants in the first arm will undergo 2 sessions of AIH each separated by a 1-week washout period. 1 week later, participants will undergo 2 sessions of Sham AIH also separated by a 1-week washout period.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor

195 Previous Clinical Trials

16,912 Total Patients Enrolled

5 Trials studying Multiple Sclerosis

343 Patients Enrolled for Multiple Sclerosis

National Multiple Sclerosis SocietyOTHER

96 Previous Clinical Trials

9,483 Total Patients Enrolled

94 Trials studying Multiple Sclerosis

9,129 Patients Enrolled for Multiple Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the eligibility criteria for individuals seeking to participate in this clinical study?

"Patients aged between 18 and 75 with a diagnosis of multiple sclerosis are eligible for inclusion in this trial, which has availability for up to 22 participants."

Answered by AI

Is it possible for patients to enroll in this ongoing clinical trial?

"According to data from clinicaltrials.gov, recruitment for this specific trial is no longer ongoing. The initial post was made on July 1st, 2024, with the latest update being on April 25th of the same year. Even though this study is not currently enrolling participants, it's worth noting that there are a substantial number of 680 other trials actively seeking volunteers at present."

Answered by AI

Do individuals younger than 30 years of age qualify to participate in this medical study?

"To be eligible for this research, individuals aged between 18 and 75 are sought after. Notably, there are 69 investigations tailored to those under 18 years old and 480 trials focused on participants above the age of 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Milap Sandhu 2024. "Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06390930.

All > Primary Progressive Multiple Sclerosis